862 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
2 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
3 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
4 Recruiting Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Drug: Vinorelbine
5 Recruiting A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Conditions: Non-Small-Cell Lung Cancer (NSCLC);   Epidermal Growth Factor Receptor Mutations
Interventions: Drug: ASP8273;   Drug: midazolam
6 Recruiting Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
Condition: Non Squamous Non Small Cell Lung Cancer
Interventions: Drug: OGX-427;   Drug: Placebo
7 Recruiting Chemotherapy for Lung Cancer in HIV-positive Patients
Conditions: Non-small Cell Lung Cancer;   Hiv-positive
Intervention: Drug: Chemotherapy
8 Not yet recruiting An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
Condition: Non Small Cell Lung Cancer Stage III
Intervention:
9 Recruiting Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
10 Recruiting Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Conditions: Brain Metastases;   Non-small Cell Lung Cancer
Intervention: Drug: Icotinib
11 Recruiting State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients
Condition: Non Small Cell Lung Cancer
Intervention:
12 Recruiting The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer
Condition: THE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer
Intervention: Drug: gemcitabine
13 Recruiting Correlation Research of Thioredoxin Reductase in Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Benign Neoplasm of Lung
Intervention:
14 Recruiting Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Condition: Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Interventions: Drug: Gefitinib;   Drug: AZD9291;   Drug: Selumetinib+Docetaxel;   Drug: Tremelimumab
15 Unknown  To Evaluate Postoperative 3D Conform Radiotherapy in Patients With IIIA (N2) Non-small Cell Lung Cancer
Conditions: Thoracic Neoplasms;   Non-small Cell Lung Cancer
Intervention: Radiation: 3D conform radiotherapy
16 Recruiting Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Condition: Non-small-cell Lung Cancer
Intervention: Drug: Icotinib plus WBRT
17 Recruiting Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer
Conditions: Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
18 Unknown  Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6;   Drug: UFT 250mg/m2, daily for 1 year
19 Recruiting MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Drug: decitabine in combination with genistein
20 Unknown  2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib plus docetaxel or pemetrexed;   Drug: erlotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years